Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2014
11/04/2014US8877227 Hydrogel nanocomposites for intraocular lens applicatons
11/04/2014US8877226 Dexamethasone formulations in a biodegradable material
11/04/2014US8877225 Controlled release copolymer formulation with improved release kinetics
11/04/2014US8877221 Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
11/04/2014US8877218 Two component interactive emulsion product
11/04/2014US8877215 Compounds with modifying activity enhanced under hypoxic conditions
11/04/2014US8877214 Pharmaceutical composition for modified release
11/04/2014US8877206 Stimulation of an immune response by cationic lipids
11/04/2014US8877203 Composition and method for preventing and treating immune-related disorder
11/04/2014US8877202 Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
11/04/2014US8877196 Methods of altering bone growth by administration of sost or wise antagonist or agonist
11/04/2014US8877188 Detection and treatment of non-dermal fibrosis
11/04/2014US8877185 Managing and treating keloids
11/04/2014US8877176 Methods for promoting wound healing and muscle regeneration with the cell signaling protein Nell1
11/04/2014US8877175 Long lasting drug formulations
11/04/2014US8877172 Zwitterionic polymer bioconjugates and related methods
11/04/2014US8877171 Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis
11/04/2014US8877169 Method of preparing hydrogel structure
11/04/2014US8877168 Aqueous liquid preparations and light-stabilized aqueous liquid preparations
11/04/2014US8877165 Solid preparation for oral application
11/04/2014US8877164 Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
11/04/2014US8875704 Nasal administration
10/2014
10/30/2014US20140325691 Regulation of endogenous gene expression in cells using zinc finger proteins
10/30/2014US20140323996 Transdermal Therapeutic System for Administering an Active Substance
10/30/2014US20140323994 Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride
10/30/2014US20140323952 Methods for prostatectomy
10/30/2014US20140323588 Topical Formulation for Pain Relief
10/30/2014US20140323587 Solid formulations of liquid biologically active agents
10/30/2014US20140323582 Composition and method for treating neurological disease
10/30/2014US20140323580 Phentermine liquid dosage form
10/30/2014US20140323578 Polymeric colorant compositions and methods of use
10/30/2014US20140323577 Methods for reducing the risk of conversion to clinically definite multiple sclerosis
10/30/2014US20140323576 Method for treating glioblastomas and other tumors
10/30/2014US20140323575 Tyrosine isomers as therapeutic agents
10/30/2014US20140323574 Infant formula with high sn-2 palmitate and oligofructose
10/30/2014US20140323573 Metabolizable salts and use thereof in diagnostics and therapy
10/30/2014US20140323571 Prevention of psychotic disorders and/or treatment of psychotic symptoms
10/30/2014US20140323570 Neuroprotection in Demyelinating Diseases
10/30/2014US20140323569 Microbial oils enriched in polyunsaturated fatty acids
10/30/2014US20140323568 Oligo-benzamide compounds and their use in treating cancers
10/30/2014US20140323566 Self-magnetic metal-salen complex compound
10/30/2014US20140323562 Thiosulfinate antioxidants and methods of use thereof
10/30/2014US20140323560 Chroman-derived anti-androgens for treatment of androgen mediated disorders
10/30/2014US20140323559 Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
10/30/2014US20140323554 Nucleotide and oligonucleotide prodrugs
10/30/2014US20140323553 Methods and Compositions Related to MiR-21 & MiR-29a, Exosome Inhibition, and Cancer Metastasis
10/30/2014US20140323549 Methods and compositions for treating diseases, disorders or injury of the nervous system
10/30/2014US20140323548 Novel amino alcohol cationic lipids for oligonucleotide delivery
10/30/2014US20140323536 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
10/30/2014US20140323533 Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
10/30/2014US20140323529 Oligomer-calcium channel blocker conjugates
10/30/2014US20140323526 Nutritional supplements
10/30/2014US20140323523 Positive allosteric modulators of nicotinic acetylcholine receptor
10/30/2014US20140323522 Method of Treating Cancer
10/30/2014US20140323518 Novel estrogen receptor ligands
10/30/2014US20140323517 Compositions and methods for injection of a biodegradable polymer-based delivery system
10/30/2014US20140323516 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
10/30/2014US20140323513 Chemotherapeutic Compositions and Methods for Treating Human Gliomas
10/30/2014US20140323512 Acrylic Polymer Formulations
10/30/2014US20140323511 Chemotherapeutic for inducing an msh2 dependent apoptotic pathway
10/30/2014US20140323507 Mycophenolic acid analogues as anti-tumor chemosensitizing agents
10/30/2014US20140323506 Combination
10/30/2014US20140323505 Oral rinse composition and method to deliver energy supplements
10/30/2014US20140323504 Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
10/30/2014US20140323503 Inhibitors of phospodiesterases 11 (pde11) and methods of use to elevate cortisol production
10/30/2014US20140323500 Nadph oxidase 4 inhibitors and use thereof
10/30/2014US20140323497 Methods and formulations of treating thrombosis with betrixaban and a p-glycoprotein inhibitor
10/30/2014US20140323496 Compositions and methods for reduction of amyloid-beta load
10/30/2014US20140323495 Stabilized Amorphous Forms of Imatinib Mesylate
10/30/2014US20140323494 N-oxides of n-phenyl-2-pyrimidine-amine derivatives
10/30/2014US20140323493 Method of treating atrial fibrillation
10/30/2014US20140323487 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
10/30/2014US20140323485 N-Substituted Heterocyclyl Carboxamides
10/30/2014US20140323484 Pharmaceutically Active Pyrazine Derivatives
10/30/2014US20140323481 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives
10/30/2014US20140323478 Serine/threonine kinase inhibitors
10/30/2014US20140323477 Serine/threonine kinase inhibitors
10/30/2014US20140323473 Compounds and methods to treat organophosphorus poisoning
10/30/2014US20140323472 Methods and compositions for the delivery of a therapeutic agent
10/30/2014US20140323465 Hcv protease inhibitors and uses thereof
10/30/2014US20140323460 Methods for Using Carboxamide, Sulfonamide and Amine Compounds
10/30/2014US20140323459 Isoxazole beta-lactamase inhibitors
10/30/2014US20140323458 Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
10/30/2014US20140323455 Methods for preserving photoreceptor cell viability following retinal detachment
10/30/2014US20140323454 Anaesthetic composition
10/30/2014US20140323453 Lipobalanced long chain testosterone esters for oral delivery
10/30/2014US20140323452 Lipobalanced long chain testosterone esters for oral delivery
10/30/2014US20140323451 Methods for administering corticosteroid formulations
10/30/2014US20140323450 Combination compositions and methods of treatment
10/30/2014US20140323449 Enema composition for treatment of ulcerative colitis having long term stability
10/30/2014US20140323448 sGC STIMULATORS
10/30/2014US20140323447 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
10/30/2014US20140323446 Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
10/30/2014US20140323445 Salicylic Acid Gel
10/30/2014US20140323444 Anti-inflammatory and antidiabetic agents
10/30/2014US20140323443 Tigecycline formulations
10/30/2014US20140323442 Small Molecule Modulators of pRb Inactivation
10/30/2014US20140323439 Therapies for hematologic malignancies
10/30/2014US20140323438 Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
10/30/2014US20140323434 Lipid conjugates in the treatment of chronic rfhinosinusitis
1 ... 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 ... 7860